DURECT Narrows Loss Amid Revenue Dip, Going Concern Doubts

TL;DR

**DURECT is on life support, but the Bausch Health acquisition is a Hail Mary pass that could save the company and its promising drug pipeline.**

AI Summary

DURECT Corporation reported a net loss of $6.497 million for the six months ended June 30, 2025, a significant improvement from the $11.343 million net loss in the same period of 2024. Total revenues decreased to $768 thousand for the six months ended June 30, 2025, down from $1.142 million in 2024, primarily due to a reduction in collaborative research and development and other revenue from $1.102 million to $749 thousand. Research and development expenses saw a substantial decrease, falling to $3.059 million in the first half of 2025 from $6.366 million in 2024, reflecting a strategic reduction in spending. Selling, general and administrative expenses also declined to $4.644 million from $5.246 million. The company's cash and cash equivalents significantly decreased to $6.502 million as of June 30, 2025, from $11.011 million at December 31, 2024, and it reported an accumulated deficit of $603.8 million, raising substantial doubt about its ability to continue as a going concern for the next twelve months. A proposed acquisition by Bausch Health Americas, Inc. was announced on July 28, 2025, which could provide a path forward.

Why It Matters

DURECT's significant accumulated deficit of $603.8 million and insufficient cash resources to meet operating plans for the next twelve months pose a critical threat to its existence, directly impacting investors' capital and employees' job security. The proposed acquisition by Bausch Health Americas, Inc. offers a potential lifeline, providing a strategic exit for current shareholders and stability for its larsucosterol development program. Without this acquisition, DURECT's ability to fund its Phase 3 clinical trial for larsucosterol in AH, a drug with Breakthrough Therapy Designation, would be severely hampered, affecting potential future treatments for patients and competitive dynamics in the biopharmaceutical market.

Risk Assessment

Risk Level: high — DURECT Corporation explicitly states it has an accumulated deficit of $603.8 million and insufficient cash resources to meet its plans for the next twelve months, raising "substantial doubt regarding the Company's ability to continue as a going concern." This is further evidenced by a net decrease in cash, cash equivalents, and restricted cash of $4.509 million for the six months ended June 30, 2025.

Analyst Insight

Investors should closely monitor the progress and completion of the proposed acquisition by Bausch Health Americas, Inc. If the merger proceeds, existing shareholders may see a defined exit value; if it fails, DURECT's severe liquidity issues and going concern risk suggest a high probability of further value erosion or cessation of operations. Consider the terms of the merger carefully before making any investment decisions.

Financial Highlights

debt To Equity

N/A

revenue

$768K

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$6.497M

eps

N/A

gross Margin

N/A

cash Position

$6.502M

revenue Growth

-32.03%

Revenue Breakdown

Key Numbers

• $6.497M — Net Loss (Decreased from $11.343M in H1 2024, indicating improved financial performance despite ongoing losses.)
• $768K — Total Revenues (Decreased from $1.142M in H1 2024, primarily due to lower collaborative R&D revenue.)
• $3.059M — Research and Development Expenses (Significantly reduced from $6.366M in H1 2024, reflecting cost-cutting measures.)
• $6.502M — Cash and Cash Equivalents (Decreased from $11.011M at Dec 31, 2024, highlighting liquidity challenges.)
• $603.8M — Accumulated Deficit (Indicates substantial historical losses and raises going concern doubts.)
• 31,054,187 — Common Stock Shares Outstanding (As of August 8, 2025, reflecting the current share count.)
• $17.5M — ALZET Product Line Sale (Completed in November 2024, providing a one-time cash infusion.)
• $4.509M — Net Decrease in Cash (For the six months ended June 30, 2025, demonstrating ongoing cash burn.)

Key Players & Entities

• DURECT CORP (company) — registrant
• Bausch Health Americas, Inc. (company) — proposed acquirer
• FDA (regulator) — U.S. Food and Drug Administration
• Lafayette Instrument Co. (company) — purchaser of ALZET product line
• Oxford Finance LLC (company) — term loan agreement provider
• $6.497 million (dollar_amount) — net loss for six months ended June 30, 2025
• $11.343 million (dollar_amount) — net loss for six months ended June 30, 2024
• $603.8 million (dollar_amount) — accumulated deficit as of June 30, 2025
• $6.502 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $17.5 million (dollar_amount) — proceeds from ALZET product line sale in November 2024

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $603.8 million and a net decrease in cash of $4.509 million for the six months ended June 30, 2025. Cash and cash equivalents decreased to $6.502 million from $11.011 million at December 31, 2024, raising substantial doubt about its ability to continue as a going concern for the next twelve months.
• Liquidity Constraints [high — financial]: Cash and cash equivalents have significantly decreased to $6.502 million as of June 30, 2025, from $11.011 million at December 31, 2024. This reduction, coupled with ongoing operating losses, indicates potential challenges in meeting short-term obligations.
• Revenue Decline [medium — operational]: Total revenues decreased to $768 thousand for the six months ended June 30, 2025, down from $1.142 million in the same period of 2024. This decline, primarily driven by lower collaborative R&D revenue, impacts the company's ability to generate income.
• Dependence on Future Funding/Acquisition [high — operational]: The company's ability to continue as a going concern is heavily reliant on the proposed acquisition by Bausch Health Americas, Inc., announced on July 28, 2025. Without this or other financing, the company may not be able to fund its operations.
• Sustained Net Losses [medium — financial]: DURECT reported a net loss of $6.497 million for the six months ended June 30, 2025. While an improvement from $11.343 million in the prior year, the continued net losses contribute to the substantial accumulated deficit.

Industry Context

DURECT operates in the biopharmaceutical industry, focusing on drug delivery technologies. This sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on strategic partnerships and acquisitions for growth and survival, especially in the face of clinical trial outcomes and funding challenges.

Regulatory Implications

As a biopharmaceutical company, DURECT is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, manufacturing compliance, and drug approval processes can significantly impact financial performance and market access. The proposed acquisition may also involve regulatory reviews.

What Investors Should Do

1. Monitor the progress and terms of the proposed acquisition by Bausch Health Americas, Inc.
2. Analyze the sustainability of cost reductions in R&D and SG&A.
3. Evaluate the company's cash burn rate and runway.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the condensed financial statements, showing reduced net loss but also decreased cash and revenue.
• 2025-07-28: Announcement of Proposed Acquisition by Bausch Health Americas, Inc. — Provides a potential solution to the going concern issue and a path forward for the company.
• 2024-11-01: ALZET Product Line Sale — Provided a one-time cash infusion, though the impact on current liquidity is still evident.
• 2024-12-31: End of Fiscal Year 2024 — Balance sheet comparison point for cash and cash equivalents.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates DURECT's history of unprofitability and contributes to the going concern doubt.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (The company's financial situation raises substantial doubt about its ability to continue as a going concern.)

Collaborative research and development

Revenue generated from partnerships with other entities for research and development activities. (A primary driver of revenue decline for DURECT in the reported period.)

Cash and Cash Equivalents

Highly liquid short-term investments that are readily convertible to known amounts of cash and which are so near their maturity that they present an insignificant risk of changes in value. (A key indicator of DURECT's short-term liquidity, which has significantly decreased.)

Year-Over-Year Comparison

Compared to the prior year period, DURECT has significantly reduced its net loss from $11.343 million to $6.497 million for the six months ended June 30, 2025, primarily due to substantial cuts in R&D and SG&A expenses. However, total revenues have also declined by 32.03% to $768 thousand, driven by lower collaborative revenue. The company's cash position has weakened, decreasing from $11.011 million at the end of 2024 to $6.502 million, intensifying concerns about its ability to continue as a going concern.

Key Financial Figures

• $0.0001 — ange on Which Registered Common Stock $0.0001 par value per share DRRX The NASDAQ

Filing Documents

• drrx-20250630.htm (10-Q) — 1929KB
• drrx-ex31_1.htm (EX-31.1) — 12KB
• drrx-ex31_2.htm (EX-31.2) — 12KB
• drrx-ex32_1.htm (EX-32.1) — 6KB
• drrx-ex32_2.htm (EX-32.2) — 7KB
• 0000950170-25-108150.txt ( ) — 9078KB
• drrx-20250630.xsd (EX-101.SCH) — 1054KB
• drrx-20250630_htm.xml (XML) — 2082KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 5 Condensed Unaudited Balance Sheets as of June 30, 2025 and December 31, 2024 5 Condensed Unaudited Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 6 Condensed Unaudited Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 7 Condensed Unaudited Statements of Cash Flows for the six months ended June 30, 2025 and 2024 8 Notes to Condensed Unaudited Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 5. Other Information 32 Item 6. Exhibits 34

Signatures

Signatures 35 2 Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. When used in this Quarterly Report on Form 10-Q or elsewhere by management from time to time, the words "believe," "anticipate," "intend," "plan," "estimate," "expect," "may," "will," "could," "potentially," "possibility," and similar expressions are forward-looking statements. Such forward-looking statements contained herein are based on current expectations and beliefs. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors. Forward-looking statements made in this report include, but are not limited to, statements about : the proposed acquisition of our company by Bausch Health Americas, Inc., a Delaware corporation ("Parent"), pursuant to an Agreement and Plan of Merger dated July 28, 2025 (the "Merger Agreement"), including the anticipated timeframe for completion of the transaction contemplated by the Merger Agreement potential uses and benefits of larsucosterol to treat alcohol-associated hepatitis ("AH"), metabolic dysfunction-associated steatohepatitis ("MASH"), or other conditions; the potential benefits of Breakthrough Therapy Designation and Fast Track Designation; the results and timing of clinical trials, including clinical trial plans and timelines for larsucosterol; the likelihood of future clinical trial results of larsucosterol being positive with statistical significance and/or similar to results from previous trials, the possible commencement of future clinical trials; our communications with the U.S. Food and Drug Administration ("FDA") regarding the trial desig

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements DURECT CORPORATION CONDENSED BA LANCE SHEETS (in thousands) (unaudited) June 30, 2025 December 31, 2024 A S S E T S Current assets: Cash and cash equivalents $ 6,502 $ 11,011 Short-term investments — 792 Accounts receivable, net 511 453 Inventories, net 291 106 Prepaid expenses and other current assets 468 813 Total current assets 7,772 13,175 Property and equipment, net 29 41 Operating lease right-of-use assets 1,683 2,135 Goodwill 2,725 2,725 Long-term restricted investments 150 150 Other long-term assets 123 123 Total assets $ 12,482 $ 18,349 L I A B I L I T I E S A N D S T O C K H O L D E R S' E Q U I T Y Current liabilities: Accounts payable $ 393 $ 309 Accrued liabilities 4,860 4,771 Deferred revenue, current portion 320 — Operating lease liabilities, current portion 1,098 1,082 Warrant liabilities 1,222 1,548 Total current liabilities 7,893 7,710 Operating lease liabilities, non-current portion 652 1,124 Other long-term liabilities 454 384 Commitments and contingencies Stockholders' equity: Common stock 23 23 Additional paid-in capital 607,288 606,439 Accumulated other comprehensive loss ( 1 ) ( 1 ) Accumulated deficit ( 603,827 ) ( 597,330 ) Stockholders' equity 3,483 9,131 Total liabilities and stockholders' equity $ 12,482 $ 18,349 The accompanying notes are an integral part of these condensed financial statements. 5 DURECT CORPORATION CONDENSED STATEMENTS O F OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share amounts) (unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Collaborative research and development and other revenue $ 428 $ 606 $ 749 $ 1,102 Product revenue 19 40 19 40 Total revenues 447 646 768 1,142 Oper

View Full Filing

View this 10-Q filing on SEC EDGAR